Protocol No.: PRESERVE-003

Phase 3, Two-stage, Randomized Study of ONC-392 Versus Docetaxel in Metastatic Non-Small Cell Lung Cancers that Progressed on PD-1/PD-L1 Inhibitors
Principal Investigator
Almubarak, Mohammed
Phase
III
Age Group
Adult
Applicable Disease Site
Lung Cancer
Participating Institution
Mary Babb Randolph Cancer Center
Contact
Rachel Harper
Clinical Research Specialist
Phone: +1 304-293-6066

View on ClinicalTrials.gov